These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1106 related articles for article (PubMed ID: 16170164)
1. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164 [TBL] [Abstract][Full Text] [Related]
2. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788 [TBL] [Abstract][Full Text] [Related]
3. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040 [TBL] [Abstract][Full Text] [Related]
4. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results. Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785 [TBL] [Abstract][Full Text] [Related]
5. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Demanes DJ; Brandt D; Schour L; Hill DR Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902 [TBL] [Abstract][Full Text] [Related]
6. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244 [TBL] [Abstract][Full Text] [Related]
7. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer. Ryan CJ; Zelefsky MJ; Heller G; Regan K; Leibel SA; Scher HI; Kelly WK Urology; 2004 Jul; 64(1):90-4. PubMed ID: 15245942 [TBL] [Abstract][Full Text] [Related]
8. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961 [TBL] [Abstract][Full Text] [Related]
9. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237 [TBL] [Abstract][Full Text] [Related]
10. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy. Zelefsky MJ; Marion C; Fuks Z; Leibel SA J Urol; 2003 Nov; 170(5):1828-32. PubMed ID: 14532785 [TBL] [Abstract][Full Text] [Related]
12. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease? Zapatero A; García-Vicente F; Martín de Vidales C; Cruz Conde A; Ibáñez Y; Fernández I; Rabadán M Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1279-85. PubMed ID: 20932659 [TBL] [Abstract][Full Text] [Related]
13. Dose escalation with three-dimensional conformal radiotherapy for prostate cancer. Is more dose really better in high-risk patients treated with androgen deprivation? Zapatero A; Ríos P; Marín A; Mínguez R; García-Vicente F Clin Oncol (R Coll Radiol); 2006 Oct; 18(8):600-7. PubMed ID: 17051950 [TBL] [Abstract][Full Text] [Related]
14. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332 [TBL] [Abstract][Full Text] [Related]
15. Definitive conformal radiotherapy for localized high-risk prostate cancer: a long-term follow-up study with PSA course. Bruns F; Franzki C; Wegener G; Karstens JH Anticancer Res; 2007; 27(4A):1847-51. PubMed ID: 17649783 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report. Valero J; Cambeiro M; Galán C; Teijeira M; Romero P; Zudaire J; Moreno M; Ciérvide R; Aristu JJ; Martínez-Monge R Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):386-92. PubMed ID: 19427741 [TBL] [Abstract][Full Text] [Related]
17. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect? Khuntia D; Reddy CA; Mahadevan A; Klein EA; Kupelian PA Cancer; 2004 Mar; 100(6):1283-92. PubMed ID: 15022298 [TBL] [Abstract][Full Text] [Related]
18. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):397-405. PubMed ID: 15890581 [TBL] [Abstract][Full Text] [Related]
19. Impact of percent positive random biopsies on biochemical outcome in prostate cancer patients treated with external beam radiotherapy with or without androgen deprivation. Igdem S; Abacioglu U; Cetin I; Alco G; Akgun Z; Sengoz M; Bekiroglu N; Turkan S; Okkan S J BUON; 2009; 14(4):629-34. PubMed ID: 20148454 [TBL] [Abstract][Full Text] [Related]
20. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Zelefsky MJ; Yamada Y; Fuks Z; Zhang Z; Hunt M; Cahlon O; Park J; Shippy A Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1028-33. PubMed ID: 18280056 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]